Ensartinib爱沙替尼,1370651-20-9

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Ensartinib

CAS No. : 1370651-20-9

MCE 国际站：Ensartinib

产品活性：Ensartinib (X-396) 是一种有效的双重的 ALK/MET 抑制剂，IC₅₀ 分别 <0.4 nM 和 0.74 nM。

研究领域：Protein Tyrosine Kinase/RTK

作用靶点：Anaplastic lymphoma kinase (ALK)  |  c-Met/HGFR

In Vitro: The ability of Ensartinib (X-396) to inhibit the growth of different cancer cell lines harboring ALK fusions or point mutations is tested. Ensartinib is potent in H3122 lung cancer cells harboring EML4-ALK E13;A20 (IC₅₀: 15nM). Ensartinib is also potent in H2228 lung cancer cells harboring EML4-ALK E6a/b; A20 (IC₅₀: 45 nM). Furthermore, X-376 is potent in SUDHL-1 lymphoma cells harboring NPM-ALK (IC₅₀: 9 nM). X-376 also inhibits SY5Y neuroblastoma cells harboring ALK F1174L, MKN-45 gastric carcinoma cells harboring MET dependent, HepG2 cells and PC-9 lung cancer cell lines harboring EGFR exon 19 del with IC₅₀s of 68 nM, 156 nM, 9.644 μM and 2.989 μM, respectively.

In Vivo: The effects of Ensartinib (X-396) in vivo against H3122 xenografts are examined. A pharmacokinetic study reveals that Ensartinib shows substantial bioavailability and moderate half-lives in vivo. Nude mice harboring H3122 xenografts are treated with Ensartinib at 25mg/kg bid. Ensartinib significantly delays the growth of tumors compared to vehicle alone. In the xenograft experiments, Ensartinib appears well-tolerated in vivo. Mouse weight is unaffected by Ensartinib treatment. Drug-treated mice appear healthy and do not display any signs of compound related toxicity. To further assess potential side effects of Ensartinib, additional systemic toxicity and toxico-kinetic studies are performed in Sprague Dawley (SD) rats. Following 10 days of repeated oral administration of Ensartinib at 20, 40, 80 mg/kg in SD rats, all animals survive to study termination. The no significant toxicity (NST) levels are determined to be 80mg/kg for Ensartinib. At NST levels, Ensartinib achieves an AUC of 66 μM×hr and a C_max of 7.19 μM.

相关产品：Afatinib  |  Cabozantinib  |  Crizotinib  |  Lorlatinib  |  Capmatinib  |  Alectinib  |  Ceritinib  |  Entrectinib  |  Brigatinib  |  Foretinib  |  Savolitinib  |  Repotrectinib  |  NVP-TAE 684  |  GSK1838705A  |  Tivantinib  |  Merestinib  |  MS4078  |  PHA-665752  |  BMS 777607  |  AZD-3463  |  Zotizalkib  |  SU11274  |  CEP-37440  |  JNJ-38877605  |  Glesatinib hydrochloride  |  Golvatinib

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds